Numerous studies revealed that miR-338, which is downregulated in GC patients, may act as a tumor, metastasis and EMT suppressor or enhance chemosensitivity, for example, by targeting PTP1B [99], P-REX2a through a PTEN/AKT axis [100], SOX5 and blocking the Wnt/β-catenin signaling pathway [101], ZEB2 and the MACC1/Met/Akt pathway [102], ACBP-3 [103], SSX2IP [104] and NRP1 [105]. Here, AKT1 is linked to neoplasm.